Geron (GERN) Revenue & Revenue Breakdown
Geron Revenue Highlights
Latest Revenue (Y)
$237.00K
Latest Revenue (Q)
$28.21M
Geron Revenue by Period
Geron Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $237.00K | -60.23% |
2022-12-31 | $596.00K | -57.21% |
2021-12-31 | $1.39M | 450.59% |
2020-12-31 | $253.00K | -45.00% |
2019-12-31 | $460.00K | -56.85% |
2018-12-31 | $1.07M | 0.09% |
2017-12-31 | $1.06M | -82.72% |
2016-12-31 | $6.16M | -83.06% |
2015-12-31 | $36.37M | 3054.47% |
2014-12-31 | $1.15M | -10.13% |
2013-12-31 | $1.28M | -52.64% |
2012-12-31 | $2.71M | 11.12% |
2011-12-31 | $2.44M | -31.57% |
2010-12-31 | $3.56M | 106.43% |
2009-12-31 | $1.73M | -38.42% |
2008-12-31 | $2.80M | -63.22% |
2007-12-31 | $7.62M | 132.59% |
2006-12-31 | $3.28M | 1030.00% |
2005-12-31 | $290.00K | -72.46% |
2004-12-31 | $1.05M | -10.31% |
2003-12-31 | $1.17M | -5.93% |
2002-12-31 | $1.25M | -65.52% |
2001-12-31 | $3.62M | -45.23% |
2000-12-31 | $6.61M | 22.39% |
1999-12-31 | $5.40M | -20.59% |
1998-12-31 | $6.80M | -6.85% |
1997-12-31 | $7.30M | 37.74% |
1996-12-31 | $5.30M | - |
Geron Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $28.21M | 3098.30% |
2024-06-30 | $882.00K | 190.13% |
2024-03-31 | $304.00K | 1221.74% |
2023-12-31 | $23.00K | -85.98% |
2023-09-30 | $164.00K | 465.52% |
2023-06-30 | $29.00K | 38.10% |
2023-03-31 | $21.00K | -79.61% |
2022-12-31 | $103.00K | -65.32% |
2022-09-30 | $297.00K | 306.85% |
2022-06-30 | $73.00K | -40.65% |
2022-03-31 | $123.00K | -88.17% |
2021-12-31 | $1.04M | 854.13% |
2021-09-30 | $109.00K | 1.87% |
2021-06-30 | $107.00K | -21.90% |
2021-03-31 | $137.00K | 174.00% |
2020-12-31 | $50.00K | -53.70% |
2020-09-30 | $108.00K | 151.16% |
2020-06-30 | $43.00K | -17.31% |
2020-03-31 | $52.00K | -69.59% |
2019-12-31 | $171.00K | 30.53% |
2019-09-30 | $131.00K | 29.70% |
2019-06-30 | $101.00K | 77.19% |
2019-03-31 | $57.00K | -84.80% |
2018-12-31 | $375.00K | 127.27% |
2018-09-30 | $165.00K | -20.67% |
2018-06-30 | $208.00K | -34.59% |
2018-03-31 | $318.00K | 66.49% |
2017-12-31 | $191.00K | 17.18% |
2017-09-30 | $163.00K | -6.32% |
2017-06-30 | $174.00K | -67.60% |
2017-03-31 | $537.00K | 471.28% |
2016-12-31 | $94.00K | -98.16% |
2016-09-30 | $5.11M | 2320.85% |
2016-06-30 | $211.00K | -71.83% |
2016-03-31 | $749.00K | 240.45% |
2015-12-31 | $220.00K | -99.38% |
2015-09-30 | $35.36M | 13988.84% |
2015-06-30 | $251.00K | -53.26% |
2015-03-31 | $537.00K | 201.69% |
2014-12-31 | $178.00K | 11.25% |
2014-09-30 | $160.00K | -53.08% |
2014-06-30 | $341.00K | -28.06% |
2014-03-31 | $474.00K | 110.67% |
2013-12-31 | $225.00K | 24.31% |
2013-09-30 | $181.00K | 61.61% |
2013-06-30 | $112.00K | -85.36% |
2013-03-31 | $765.00K | 11.03% |
2012-12-31 | $689.00K | 8.33% |
2012-09-30 | $636.00K | 389.23% |
2012-06-30 | $130.00K | -89.63% |
2012-03-31 | $1.25M | 399.60% |
2011-12-31 | $251.00K | 14.09% |
2011-09-30 | $220.00K | -52.38% |
2011-06-30 | $462.00K | -69.30% |
2011-03-31 | $1.50M | 37.07% |
2010-12-31 | $1.10M | 101.10% |
2010-09-30 | $546.00K | -45.45% |
2010-06-30 | $1.00M | 9.04% |
2010-03-31 | $918.00K | 51.74% |
2009-12-31 | $605.00K | 22.47% |
2009-09-30 | $494.00K | 169.95% |
2009-06-30 | $183.00K | -58.78% |
2009-03-31 | $444.00K | -18.38% |
2008-12-31 | $544.00K | 48.23% |
2008-09-30 | $367.00K | 85.35% |
2008-06-30 | $198.00K | -88.31% |
2008-03-31 | $1.69M | -63.86% |
2007-12-31 | $4.69M | - |
Geron Revenue Breakdown
Geron Revenue Breakdown by Product
Quarterly Revenue by Product
Product/Service | Sep 24 |
---|---|
Chargeback And Distributor Service Fees | $-4.00M |
Government Rebates | $-364.00K |
Product | $28.21M |
Revenues Before Adjustments | $32.66M |
Sales Returns And Allowance | $-82.00K |
Total Gross To Net Adjustments | $-4.45M |
Geron Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
SRPT | Sarepta Therapeutics | $1.24B | $362.93M |
PTCT | PTC Therapeutics | $937.82M | $135.42M |
TGTX | TG Therapeutics | $233.66M | $83.88M |
GERN | Geron | $237.00K | $28.21M |
CWBR | CohBar | - | - |
XFOR | X4 Pharmaceuticals | - | $563.00K |
AVRO | AVROBIO | - | - |
VKTX | Viking Therapeutics | - | - |
PDSB | PDS Bio | - | - |
ZURA | Zura Bio | - | - |
ELEV | Elevation Oncology | - | - |
MDGL | Madrigal Pharmaceuticals | - | $62.17M |
OCEA | Ocean Biomedical | - | - |
IMMX | Immix Biopharma | - | - |
HEPA | Hepion Pharmaceuticals | - | - |
ENVB | Enveric Biosciences | - | - |
EFTR | eFFECTOR Therapeutics | - | - |
GERN Revenue FAQ
What is Geron’s yearly revenue?
Geron's yearly revenue for 2023 was $237K, representing a decrease of -60.23% compared to 2022. The company's yearly revenue for 2022 was $596K, representing a decrease of -57.21% compared to 2021. GERN's yearly revenue for 2021 was $1.39M, representing an increase of 450.59% compared to 2020.
What is Geron’s quarterly revenue?
Geron's quarterly revenue for Q3 2024 was $28.21M, a 3098.30% increase from the previous quarter (Q2 2024), and a 17100.61% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $882K, a 190.13% increase from the previous quarter (Q1 2024), and a 2941.38% increase year-over-year (Q2 2023). GERN's quarterly revenue for Q1 2024 was $304K, a 1221.74% increase from the previous quarter (Q4 2023), and a 1347.62% increase year-over-year (Q1 2023).
What is Geron’s revenue growth rate?
Geron's revenue growth rate for the last 3 years (2021-2023) was -82.99%, and for the last 5 years (2019-2023) was -48.48%.